Experts Matter. Find Yours.
Connect for media, speaking, professional opportunities & more.
Assessing Biden's "Green Infrastructure" Plan From a Climate Perspective
In a virtual climate summit attended by leaders from all over the globe, President Joseph Biden announced plans for the United States to cut carbon emissions by as much as 52% by the year 2030. This commitment was outlined in what the Biden administration is calling a "green infrastructure" bill, one that has echoes of the Obama-era Green New Deal. Samantha Chapman, PhD, a biology professor at Villanova University and co-director of the Center for Biodiversity and Ecosystem Stewardship, recently broke down the pros and cons of the bill with KYW Newsradio's Matt Leon. According to Dr. Chapman, the bill addresses what she identifies as the two major strategies for mitigating the negative effects of our warming planet: "preventing more climate change and adapting to climate change." Dr. Chapman considers that the strength of the bill lies in what she and Matt Leon refer to as "base hits" rather than the "home run" structure of the Green New Deal, meaning that Biden's plan relies on smaller, easily achievable goals—like incentivizing a switch to a more sustainable type of cement for building bridges—rather than sweeping reform in an effort to get the bill passed. Dr. Chapman calls the improvement of the power grid, which would support the manufacturing of electric cars and ease our nation's reliance on fossil fuels, "one of the biggest things in the bill." The professor also notes that she is hopeful about the installation of broadband in remote areas allowing for wider internet access and investment in energy-efficient affordable housing and job training to support communities that rely on the fossil fuel industries. "You can't just shut these people's livelihoods down and say 'okay, good luck' or just give them a payout. People want to have jobs that fulfill them," says Dr. Chapman. This direction, focusing on infrastructure with climate and equity at the center of the conversation, is in line with the Biden campaign's slogan to "build back better." Dr. Chapman points out that this bill creates an opportunity to focus on the word "better" by reevaluating the definition of infrastructure itself. "What is infrastructure?" she asks. "Is clean air infrastructure? Is clean water infrastructure? We know that natural infrastructures [feedback systems like our waterways and forests]—and we still have a lot of them in the U.S., thankfully—give us a buffer against climate change." As a climate scientist specializing in coastal ecosystems, Dr. Chapman told Leon she hopes to see an emphasis on these types of natural infrastructures. "I think that salt marshes and mangroves are really important in buffering our coast against big storms, so I want to see explicitly that we are going restore these places. It would be good for biodiversity; it would be good for people hanging out and kayaking; and it would help us protect against these big storms that are coming whether or not we cap our emissions. I think I would like to see more of these green barriers along our coast rather than big seawalls, and I haven't seen that exactly yet, but again the fine print's not there," she points out. "The bill's not done." Finally, Dr. Chapman spoke to how this infrastructure bill could have an impact on the future of the country if it is passed and observed. "I think there's still work to do on things like forests and biodiversity; there's always more work to do. I think it would be a massive step in the right direction. And then we'd have to go to the rest of the world and start doing some work there."
The Food and Drug Administration and the Centers for Disease Control and Prevention recently lifted the pause on the Johnson & Johnson COVID-19 vaccine. The agencies had shelved the vaccine after it was linked to cases of an extremely rare blood clotting disorder. Public health officials are now concerned that as news gets out about the potential side effects of the Johnson & Johnson vaccine, some members of the Black and Hispanic communities may opt out of what could be a life-saving act. “To the Black and Hispanic communities, there has been a long history of untrustworthy behavior by health care systems, and the current issue with Johnson & Johnson may have worsened some hesitancy,” said Dr. Justin X. Moore, an epidemiologist in the Department of Population Health Sciences at the Medical College of Georgia. “To overcome this barrier, companies must continue being open about side effects of the vaccine, and health care workers must be empathetic and listen to their patients’ concerns.” Vaccine safety and the importance of everyone being vaccinated is crucial as America looks to get to the light at the end of this pandemic. If you are a journalist covering COVID-19 and the issues surrounding vaccine hesitancy, then let our experts help. Dr. Justin Moore is an expert in spatial epidemiology and an associate professor at the Institute of Public and Preventive Health at Augusta University. He is available to speak with media regarding this topic – simply click on his name to arrange an interview.
Ambitious student research collaborations with faculty members often lead to much more than good grades. The mentorships encourage professional growth, confidence and creativity, even in the midst of a pandemic. Georgia Southern University’s Spring 2021 Honors Research Symposium, which is being held virtually April 26 through April 30, will showcase faculty-student partnerships through a broad range of scholarly and creative research projects produced by more than 100 honors students across multiple disciplines on the Statesboro and Armstrong campuses. A few of the presenters include: Chelsea Riley, a triple major in international studies, political science and Spanish, worked with political science and international studies professor Srobana Bhattacharya, Ph.D., on her thesis, “The Culture Gap: The Role of Culture in Successful Refugee Settlement.” History and English major Jacey Thomas, mentored by associate professor of history Alan Downs, Ph.D., will present, “Irish Rock Music amid a Time of Troubles: Thin Lizzy and U2 as a Bridge During a Time of Division.” Biology major Susan Ihejirika’s presentation, “A Forward Genetic Screen to Identify Human Genes of Interest and Their Roles in Ovarian Cancer,” was guided by biology assistant professor Dongyu Jia, Ph.D. The Honors College, as the university-wide center for excellence in undergraduate education, plays a crucial role with undergraduate research at Georgia Southern. Since the beginning of the College, students have been required to complete honors theses or capstone projects. The faculty-mentored projects have spanned traditional research models, applied research and creative activities in all academic colleges and majors. “Through faculty-mentored research and scholarly activities, honors students create new knowledge and the Honors Research Symposium is the venue where we share it with the broader scholarly community,” said Honors College Dean Steven Engel, Ph.D. “ I am proud of the fact that they have been able to complete these projects despite the challenges of the past year.” Presentations will be posted on YouTube and the comments section will be open for audience engagement with presenters. If you're a journalist looking to learn more about this year’s Honors Research Symposium — simply reach out to Georgia Southern Director of Communications Jennifer Wise at jwise@georgiasouthern.edu.
Self-Built Protein Coatings Could Improve Biomedical Devices
Fouling is a natural phenomenon that describes the tendency of proteins in water to adhere to nearby surfaces. It’s what causes unwanted deposits of protein to form during some food production or on biomedical implants, causing them to fail. Using her expertise in developing bio-inspired materials for use in human health, R. Helen Zha, an assistant professor of chemical and biological engineering will harness this process found in nature to develop a versatile and accessible approach for modifying solid surfaces. With the support of a more than $592,000 National Science Foundation Faculty Early Career Development (CAREER) grant, Zha will use silk fibroin — a protein that naturally assembles itself — to grow a nanoscale film on the surface of an object. This approach only requires a beaker, water, salt, and the protein, which Zha said makes it biocompatible, safe, ecofriendly, and accessible beyond the walls of a lab. Zha has demonstrated that this approach can work and, in some cases, even increase the therapeutic benefits of an implant. In research published in ACS Biomaterials Science & Engineering, Zha collaborated with Ryan Gilbert, a professor of biomedical engineering at Rensselaer, to modify the surface of a fibrous scaffold that was developed by Gilbert’s lab in order to encourage the growth of neurites at the site of nerve damage. The importance of this research could expand beyond the protein Zha and her lab are working with. This approach, she explained, could be applied to any number of proteins and macromolecules.
New prostate cancer urine test shows how aggressive disease is and could reduce invasive biopsies
Researchers from the University of East Anglia have developed a new urine test for prostate cancer which also shows how aggressive the disease is. A new study shows how an experimental new test called ‘ExoGrail’ has the potential to revolutionise how patients with suspected prostate cancer are risk-assessed prior to an invasive biopsy. The research team say their new test could reduce the number of unnecessary prostate cancer biopsies by 35 per cent. Prostate cancer is the most common cancer in men in the UK. It usually develops slowly and the majority of cancers will not require treatment in a man’s lifetime. The most commonly used tests for prostate cancer include blood tests, a physical examination known as a digital rectal examination (DRE), an MRI scan or an invasive biopsy. However, doctors struggle to predict which tumours will become aggressive, making it hard to decide on treatment for many men. Lead researcher Dr Dan Brewer, from UEA’s Norwich Medical School, said: “While prostate cancer is responsible for a large proportion of all male cancer deaths, it is more commonly a disease men die with rather than from. “Therefore, there is a desperate need for improvements in diagnosing and predicting outcomes for prostate cancer patients to minimise over-diagnosis and overtreatment whilst appropriately treating men with aggressive disease, especially if this can be done without taking an invasive biopsy. “Invasive biopsies come at considerable economic, psychological and societal cost to patients and healthcare systems alike.” The research team developed the new ExoGrail urine test by combining two biomarker sources - measurements of a protein-marker called EN2 and the levels of gene expression of 10 genes related to prostate cancer risk. It builds on previously developed tests called PUR and ExoMeth. They tested it using urine samples from 207 patients who had been undergone a biopsy for prostate cancer at the Norfolk and Norwich University Hospital (NNUH). When the urine results were compared to biopsy results, the study showed that the test had successfully shown which patients had prostate cancer and which did not. The ExoGrail test also provided risk scores for patients and highlighted those for which an invasive biopsy would have been beneficial. The findings show that using information from multiple, non-invasive biomarker sources has the potential to greatly improve how patients with suspected prostate cancer are risk-assessed prior to an invasive biopsy. Dr Brewer said: “Our new urine test not only shows whether a patient has prostate cancer, but it importantly shows how aggressive the disease is. This allows patients and doctors to select the correct treatment. And it has the potential to reduce the number of unnecessary biopsies by 35 per cent.” The research team was led by Dr Shea Connell, Prof Colin Cooper, Dr Daniel Brewer and Dr Jeremy Clark, all from UEA’s Norwich Medical School, in collaboration with the Norfolk and Norwich University Hospital, the University of Surrey, the University of Bradford, The Earlham Institute, and The Movember GAP1 Urine Biomarker Consortium. The urine biomarker research was funded by the Movember GAP1 Urine Biomarker project, Prostate Cancer UK, The Masonic Charitable Foundation, The Bob Champion Cancer Trust, the King family, The Andy Ripley Memorial Fund, the Hargrave Foundation, Norfolk Freemasons and the Tesco Centenary Grant. Paul Villanti, executive director of programmes at Movember, said: “We are proud to have supported the development of the ExoGrail urine test as part of our Global Action Plan Urine Biomarker project. “Having non-invasive tests which can accurately show how aggressive a man’s prostate cancer is not only reduces the number of men having to undergo painful biopsies, but also ensures that the right course of treatment for the patient is selected more quickly.” ‘Integration of Urinary EN2 Protein & Cell-Free RNA Data in the Development of a Multivariable Risk Model for the Detection of Prostate Cancer Prior to Biopsy’ is published in the journal Cancers on Tuesday, April 27, 2021.
Novel coronavirus discovered in British bats
A coronavirus related to the virus that causes Covid-19 in humans has been found in UK horseshoe bats – according to new collaborative research from the University of East Anglia, ZSL (Zoological Society of London), and Public Health England (PHE). However, there is no evidence that this novel virus has been transmitted to humans, or that it could in future, unless it mutates. UEA researchers collected faecal samples from more than 50 lesser horseshoe bats in Somerset, Gloucestershire and Wales and sent them for viral analysis at Public Health England. Genome sequencing found a novel coronavirus in one of the bat samples, which the team have named ‘RhGB01’. Due to the rapid response nature of this research, it has not yet been peer reviewed. It is the first time that a sarbecovirus (SARS-related coronavirus) has been found in a lesser horseshoe bat and the first to be discovered in the UK. The research team say that these bats will almost certainly have harboured the virus for a very long time. And it has been found now, because this is the first time that they have been tested. Importantly, this novel virus is unlikely to pose a direct risk to humans, unless it mutates. A mutation could happen if a human infected with Covid-19 passes it to an infected bat, so anyone coming into contact with bats or their droppings, for example those engaged in caving or bat protection, should wear appropriate PPE. Prof Diana Bell, an expert in emerging zoonotic diseases from UEA’s School of Biological Sciences, said: “Horseshoe bats are found across Europe, Africa, Asia and Australia and the bats we tested lie at the western extreme of their range. “Similar viruses have been found in other horseshoe bat species in China, South East Asia and Eastern Europe. “Our research extends both the geographic and species ranges of these types of viruses and suggests their more widespread presence across more than 90 species of horseshoe bats. “These bats will almost certainly have harboured this virus for a very long time – probably many thousands of years. We didn’t know about it before because this is the first time that such tests have been carried out in UK bats. “We already know that there are different coronaviruses in many other mammal species too,” she said. “This is a case of ‘seek and you will find’. “Research into the origins of SARS-CoV-2, the virus that causes Covid-19 in humans, has focussed on horseshoe bats - but there are some 1,400 other bat species and they comprise 20 per cent of known mammals. “Our findings highlight the need for robust genotype testing for these types of viruses in bat populations around the world. And it raises an important question about what other animals carry these types of viruses.” Prof Andrew Cunningham, from the Zoological Society of London, said: “Our findings highlight that the natural distribution of sarbecoviruses and opportunities for recombination through intermediate host co-infection have been underestimated. “This UK virus is not a threat to humans because the receptor binding domain (RBD) – the part of the virus that attaches to host cells to infect them - is not compatible with being able to infect human cells. “But the problem is that any bat harbouring a SARS-like coronavirus can act as a melting pot for virus mutation. So if a bat with the RhGB01 infection we found were to become infected with SARS-CoV-2, there is a risk that these viruses would hybridise and a new virus emerge with the RBD of SARS-CoV-2, and so be able to infect people. “Preventing transmission of SARS-CoV-2 from humans to bats, and hence reducing opportunities for virus mutation, is critical with the current global mass vaccination campaign against this virus.” Prof Bell added: “The main risks would be for example a bat rehabilitator looking after a rescued animal and infecting it with SARS-CoV2 - which would provide an opportunity for genetic recombination if it is already carrying another sarbecovirus. “Anyone coming into contact with bats or their droppings, such as bat rescuers or cavers, should wear appropriate PPE – in order to reduce the risk of a mutation occurring. “We need to apply stringent regulations globally for anyone handling bats and other wild animals,” she added. The new virus falls within the subgroup of coronaviruses called sarbecoviruses which contains both SARS-CoV-2 (responsible for the current pandemic) and SARS-CoV (responsible for the initial 2003 SARS outbreak in humans). Further analysis compared the virus with those found in other horseshoe bat species in China, South East Asia and Europe and showed that its closest relative was discovered in a Blasius’s bat from Bulgaria in 2008. Ivana’s story The UK discovery was made by undergraduate ecology student Ivana Murphy, from UEA’s School of Biological Sciences, who collected bat droppings as part of her final year research dissertation. Jack Crook conducted the genetic analyses in partnership with other researchers at PHE. A total of 53 bats were captured, and their faeces collected in sterile bags. The research was conducted under strict Health and Safety protocols. Full PPE was worn and Ivana was regularly tested for Covid-19 to avoid any chance of cross contamination. The bats were released immediately after their droppings had been collected. Ivana said: “I am very fortunate to be surrounded by so many experts in their fields, which has allowed me access to resources that many undergraduates wouldn’t have. I feel extremely lucky to have been able to conduct such an advanced study.” “We weren’t shocked by the results, but I am extremely eager to carry out further research. “I chose to study ecology at UEA as I have a passion for trying to protect and conserve nature. I wanted a better understanding of the global situation and so chose UEA to study ecology and conservation. “The plan after graduation is to do an extended study of viruses in UK bats, very similar to the one I carried out as an undergraduate. There is still a lot more to understand and I am extremely excited to see what else we can find out.” But she says that she doesn’t want her research to turn people against bats. “More than anything, I’m worried that people may suddenly start fearing and persecuting bats, which is the last thing I would want and would be unnecessary. As like all wildlife, if left alone they do not pose any threat.” ‘Metagenomic identification of a new sarbecovirus from horseshoe bats in Europe’ is published on the Research Square pre-print server. Read the full story, including a Q&A with all you need to know.
Smell training, not steroids, best treatment for Covid-19 smell loss
Steroids should not be used to treat smell loss caused by Covid-19 according to an international group of smell experts, including Prof Carl Philpott from the University of East Anglia. Smell loss is a prominent symptom of Covid-19, and the pandemic is leaving many people with long-term smell loss. But a new study published today shows that corticosteroids - a class of drug that lowers inflammation in the body – are not recommended to treat smell loss due to Covid-19. Instead, the team recommend ‘smell training’ – a process that involves sniffing at least four different odours twice a day for several months. Smell loss expert Prof Carl Philpott from UEA’s Norwich Medical School, said: “The huge rise in smell loss caused by Covid-19 has created an unprecedented worldwide demand for treatment. “Around one in five people who experience smell loss as a result of Covid-19 report that their sense of smell has not returned to normal eight weeks after falling ill. “Corticosteroids are a class of drug that lowers inflammation in the body. Doctors often prescribe them to help treat conditions such as asthma, and they have been considered as a therapeutic option for smell loss caused by Covid-19. “But they have well-known potential side effects including fluid retention, high blood pressure, and problems with mood swings and behaviour.” The team carried out a systematic evidence-based review to see whether corticosteroids could help people regain their sense of smell. Prof Philpott said: “What we found that there is very little evidence that corticosteroids will help with smell loss. And because they have well known potential adverse side effects, our advice is that they should not be prescribed as a treatment for post-viral smell loss. "There might be a case for using oral corticosteroids to eliminate the possibility of another cause for smell loss actually being a confounding factor, for example chronic sinusitis – this is obviously more of a diagnostic role than as a treatment for viral smell loss. “Luckily most people who experience smell loss as a result of Covid-19 will regain their sense of smell spontaneously. Research shows that 90 per cent of people will have fully recovered their sense of smell after six months. “But we do know that smell training could be helpful. This involves sniffing at least four different odours twice a day every day for several months. It has emerged as a cheap, simple and side-effect free treatment option for various causes of smell loss, including Covid-19. “It aims to help recovery based on neuroplasticity - the brain’s ability to reorganise itself to compensate for a change or injury,” he added. The research was led by researchers at the Cliniques universitaires Saint-Luc in Brussels (Belgium) in collaboration with the Univeristé catholique de Louvain, Brussels (Belgium), the University of East Anglia (UK), Biruni University, Istanbul (Turkey), Aarhus University (Denmark), Université du Québec à Trois-Rivières (Canada), Geneve University Hospitals (Switzerland), Harvard University (USA), Aristotle University, Thessaloniki (Greece), University of Insubriae (Italy), University of Vienna (Austria), the University of Chicago (USA) and the University of Colorado (USA). ‘Systemic corticosteroids in COVID-19 related smell dysfunction: an international view’ is published in the journal International Forum of Allergy & Rhinology.
ChristianaCare also ranks as No. 1 overall employer for diversity and inclusion in Delaware, No. 14 among U.S. health systems (WILMINGTON, Del. – April 23) magazine ranked ChristianaCare as one of the best employers for diversity and inclusion in the United States in its list of Best Employers for Diversity 2021. ChristianaCare also ranked as the No. 1 employer for diversity in Delaware and the No. 14 health system for diversity in the nation. ChristianaCare ranked 121st out of the 500 employers that were recognized. “At ChristianaCare, our mission is simple, but profound – we take care of people,” said Janice Nevin, M.D., MPH, president and CEO of ChristianaCare, which is Delaware’s largest private employer. “And caring for people means that we work together, guided by our values of love and excellence, to bring equity and inclusion to everyone we serve, including our own caregivers. We are committed to building a workforce that reflects the diverse communities we serve, as we aspire to deliver high-quality, accessible care and achieve health equity.” ChristianaCare has committed to being an anti-racism organization and works to ensure that commitment is reflected through the organization’s policies, programs, and practices. (Read more about ChristianaCare’s anti-racism commitment here.) ChristianaCare’s inclusion efforts also include the launch of 10 employee resource groups, which connect caregivers who have a common interest or bond with one another. Formed by employees across all demographics – such as disability, gender, race, military status, national origin, sexual orientation, etc. – these voluntary grassroots groups work to improve inclusion and diversity at ChristianaCare. More than 750 caregivers at ChristianaCare participate in employee resource groups. ChristianaCare also recently launched LeadershipDNA, a new leadership development program that is specifically targeted to underrepresented, diverse populations and is designed to foster professional and career development. “We are grateful for this recognition, which affirms that our organization is committed to taking on the meaningful work to help our caregivers be exceptional today and even better tomorrow,” said Pamela Ridgeway, chief diversity officer and vice president of Inclusion and Diversity at ChristianaCare. “The fact that our caregivers can see the value and feel the impact of our inclusion and diversity efforts illustrates the importance for us to continue to push onward.” Forbes’ Best Employers for Diversity were identified from an independent survey of more than 50,000 U.S. employees working for companies employing at least 1,000 people in their U.S. operations. The employees were asked to give their opinion on a series of statements surrounding the topic of age, gender equality, ethnicity, disability, LGBTQ+, and general diversity concerning their own employer. The survey also gave survey participants the chance to evaluate other employers in their respective industries that stand out with regard to diversity. Only the recommendations of minority groups were considered. Also factored in was diversity engagement amongst managers and diversity among leadership. About ChristianaCare Headquartered in Wilmington, Delaware, ChristianaCare is one of the country’s most dynamic health care organizations, centered on improving health outcomes, making high-quality care more accessible and lowering health care costs. ChristianaCare includes an extensive network of primary care and outpatient services, home health care, urgent care centers, three hospitals (1,299 beds), a freestanding emergency department, a Level I trauma center and a Level III neonatal intensive care unit, a comprehensive stroke center and regional centers of excellence in heart and vascular care, cancer care and women’s health. It also includes the pioneering Gene Editing Institute. ChristianaCare is nationally recognized as a great place to work, rated by Forbes as the 5th best health system to work for in the United States and by IDG Computerworld as one of the nation’s Best Places to Work in IT. ChristianaCare is rated by HealthGrades as one of America’s 50 Best Hospitals and continually ranked among the nation’s best by U.S. News & World Report, Newsweek and other national quality ratings. ChristianaCare is a nonprofit teaching health system with more than 260 residents and fellows. With the unique CareVio™ data-powered care coordination service and a focus on population health and value-based care, ChristianaCare is shaping the future of health care. ####
COVID expert: Prof Lawrence Young, UK
Professor Lawrence Young of the University of Warwick is one of the go-to experts in the UK on COVID-19. A Professor of Molecular Oncology at Warwick Medical School, he can comment on many aspects of the pandemic -- from the nature of the virus itself and its effects in patients, to its impacts on hospitals and wider society. He regularly features on TV, radio, and newspapers in the UK and worldwide, including: If you would like to book an interview with Prof. Young, contact press@warwick.ac.uk or L.Walton.1@warwick.ac.uk
Combating Vaccine Hesitancy Through Messaging
As vaccine hesitancy becomes a threat to Americans' decision to get the COVID vaccine, persuasive messaging is at the forefront of changing people's minds. Allyson Levin, PhD, a visiting assistant professor of communication, believes social media messaging plays a key role—and that post-vaccination selfies can actually help convince people to get the vaccine. "When we don't know what to do, we look to others to guide our behavior," stated Dr. Levin. "It is really important when we see people who share online that they were vaccinated—who are close to us, our friends or family and people we look up to like influencers and celebrities." Further, online communities create a world where it appears that people are getting vaccinated actively. "If we look around and see an environment where people are getting vaccinated, we will want to get vaccinated as well. That will encourage vaccination. At least if we trust those people around us," said Dr. Levin. Dr. Levin also contends that the social media platform TikTok can be extremely useful when information is "scientifically valid, evidence-based and coming from people who understand science like medical professionals." "A unique opportunity we have with TikTok is that users are receiving health information when they aren't looking for it," said Dr. Levin. In addition, she notes the incredible impact company advertisements endorsing COVID vaccinations have had on their wider acceptance. "At the end of the day, it is wonderful that brands are amplifying these messages, like Budweiser donating their airtime during the Super Bowl. There is an element of public relations, too: The brands look good for promoting these messages. But the more people that see these messages, the better." However, Dr. Levin pointed out that, while messaging is extremely important, vaccine availability is crucial. "Access is equally important. Unless people can actually have access to the vaccinations, the message is just one part of it," stated Dr. Levin.